Place of tiotriazoline in the gallery of modern metabolitotropic medicines
| Autor: | I. F. Bielenichev, V. A. Vіzіr, V. Yo. Mamchur, O. V. Kuriata |
|---|---|
| Jazyk: | English<br />Russian<br />Ukrainian |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Zaporožskij Medicinskij Žurnal, Vol 21, Iss 1, Pp 118-128 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2310-1210 2306-4145 |
| DOI: | 10.14739/2310-1210.2019.1.155856 |
| Popis: | We want to show pharmacological characterization of Tiotriazoline, based on results of tentative analysis and clinical research, also features of its therapeutic action and advantage over another metabolitotropic cardio protectors. As a result of the literary sources analysis, we found out that the team of scientists led by professor I. A. Mazur had developed and created qualitatively new innovative medicine of cation-anionic action, namely Thiotriazolin, which is based on 1,2,4-triazole molecule and was selected among more than 1000 compounds. This drug is the first representative of the class of metabolitotropic cyto- and cardioprotectors and it exhibits anti-ischemic, cardioprotective, antioxidant, energotropic, membrane-protective and immunomodulating properties and is widely used to treat diseases of the cardiovascular system and eye diseases. The mechanism of action of Thiotriazolin is to increase the expression of antioxidant enzymes, reduce the concentration of free radicals, activate a compensatory malate-aspartate shunt of energy production, normalize the work of the Krebs cycle, and initiate Red / Oxi-dependent expression of transcription factors in ischemia. Using the example of pharmacodynamics and clinical efficacy of Thiotriazoline, the modern concept of metabolitotropic cardioprotection was further developed. Thiotriazolin belongs to V class of toxicity (practically non-toxic substances). Thiotriazolin reduces the number and duration of ischemia episodes, cardiac arrhythmias, increases tolerance to physical activity, and also improves the quality and lifetime (assessed using the Minnesota questionnaire and Nottingham health profile) of patients with cardiovascular pathology (stable angina, myocardial infarction, post infarction myocardial remodeling, chronic heart failure, arrhythmias). We can add that application of Tiotriazolin have social value because it leads to the decrease in mortality and disability of patients with pathology of the cardiovascular system, also decrease in blindness after injury, eye burns, cataracts. The economic efficiency from the Thiotriazolin use is also indicated by reducing the time spent by patients with pathology of the cardiovascular system in the hospital, as a result reducing the state's expenses for the treatment and rehabilitation of this category of patients; also by increase the efficiency of persons whose activities are associated with increased load on the visual analyzer |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|